 However, from 2008 to 2010, Galenika rapidly accumulated debt to the point where it owed 130 million euros.Once controlling a majority market share in Serbia and former Yugoslavia, during the 2010s it became indebted company.By the 2010s, most of the Serbian formerly domestically controlled pharmaceutical market, has shifted in foreign hands.